Nafithromycin:
India has achieved a groundbreaking milestone in the fight against antimicrobial resistance (AMR) with the development of Nafithromycin, the country’s first indigenous macrolide antibiotic.
- Developed by: Wockhardt Ltd., with support from the Biotechnology Industry Research Assistance Council (BIRAC) under the Biotech Industry Program.
- Aim: To combat Community-Acquired Bacterial Pneumonia (CABP) and address infections caused by drug-resistant bacteria.
- Reduce the global and national burden of antimicrobial resistance.
- 10 times more effective than existing treatments like azithromycin.
- Offers a three-day treatment regimen, significantly reducing recovery time.
- Effective against typical and atypical drug-resistant bacteria, with superior safety and minimal side effects.
